SLN
Silence Therapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$14.59
−1.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 614.3K | 559.0K | 43.3M | 25.4M | 17.7M |
| Cost of Revenue | 301.0K | 215.0K | 11.8M | 10.3M | 11.0M |
| Gross Profit | 313.3K | 344.0K | 31.4M | 15.1M | 6.7M |
| Operating Expenses | |||||
| R&D Expense | 46.0M | 67.8M | 67.9M | 44.0M | 35.5M |
| SG&A Expense | 21.2M | 22.3M | 26.9M | 20.6M | 20.9M |
| General & Admin Expense | 21.2M | 22.3M | 26.9M | 20.6M | 20.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (45.7K) | — | — | — | — |
| Total Operating Expenses | 67.1M | 90.1M | 94.8M | 64.7M | 56.4M |
| Cost and Expenses | 67.5M | 90.3M | 106.6M | 75.0M | 67.4M |
| Operating Income (EBIT) | (66.8M) | (89.8M) | (63.3M) | (49.6M) | (49.8M) |
| Non-Operating | |||||
| Interest Income | — | 3.5M | 4.5M | 1.4M | 226.0K |
| Interest Expense | — | — | — | 34.0K | 47.0K |
| Net Interest Income | — | 3.5M | 4.5M | 1.4M | 179.0K |
| Other Non-Op Income/Expense | 6.9M | 1.2M | 18.9M | (706.0K) | 9.3M |
| Non-Operating Income (excl Interest) | (6.1M) | (1.2M) | (13.7M) | 672.0K | (9.3M) |
| EBT (Pre-Tax Income) | (59.9M) | (88.6M) | (44.5M) | (50.3M) | (40.5M) |
| Income Tax Expense | 2.0K | 11.0K | 845.0K | (7.0M) | 560.9K |
| Bottom Line | |||||
| Net Income | (60.0M) | (88.6M) | (45.3M) | (43.3M) | (41.0M) |
| Earnings from Cont. Ops | (60.0M) | (88.6M) | (45.3M) | (43.3M) | (41.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (60.0M) | (88.6M) | (45.3M) | (43.3M) | (41.0M) |
| Per Share | |||||
| Basic EPS | ($3.81) | ($5.67) | ($2.37) | ($3.48) | ($3.78) |
| Diluted EPS | ($3.81) | ($5.67) | ($2.37) | ($3.48) | ($3.78) |
| Revenue Per Share | $0.04 | $0.04 | $2.81 | $2.05 | $1.64 |
| Shares | |||||
| Basic Shares Outstanding | 15.7M | 15.7M | 15.4M | 12.4M | 10.7M |
| Diluted Shares Outstanding | 15.7M | 15.7M | 15.4M | 12.4M | 10.7M |
| Profitability Metrics | |||||
| EBITDA | (60.3M) | (88.0M) | (49.0M) | (49.8M) | (39.9M) |
| D&A | 483.0K | 555.0K | 593.0K | 498.0K | 485.9K |
| EBIT | (60.8M) | (88.6M) | (49.6M) | (50.3M) | (40.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026